$839.96
14.30%
NYSE, Apr 17, 10:26 pm CET
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Eli Lilly and Company Stock price

$839.96
+15.20 1.84% 1M
-77.16 8.41% 6M
+67.96 8.80% YTD
+89.19 11.88% 1Y
+541.14 181.09% 3Y
+682.67 434.02% 5Y
+767.49 1,059.05% 10Y
NYSE, Closing price Thu, Apr 17 2025
+105.06 14.30%
ISIN
US5324571083
Symbol
LLY
Sector
Industry

Key metrics

Market capitalization $796.27b
Enterprise Value $826.57b
P/E (TTM) P/E ratio 73.11
EV/FCF (TTM) EV/FCF 219.83
EV/Sales (TTM) EV/Sales 18.35
P/S ratio (TTM) P/S ratio 17.68
P/B ratio (TTM) P/B ratio 56.08
Dividend yield 0.62%
Last dividend (FY24) $5.20
Revenue growth (TTM) Revenue growth 32.00%
Revenue (TTM) Revenue $45.04b
EBIT (operating result TTM) EBIT $17.04b
Free Cash Flow (TTM) Free Cash Flow $3.76b
Cash position $3.42b
EPS (TTM) EPS $11.49
P/E forward 36.69
P/S forward 13.34
EV/Sales forward 13.85
Short interest 0.88%
Show more

Is Eli Lilly and Company a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Eli Lilly and Company Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Eli Lilly and Company forecast:

25x Buy
89%
3x Hold
11%

Analyst Opinions

28 Analysts have issued a Eli Lilly and Company forecast:

Buy
89%
Hold
11%

Financial data from Eli Lilly and Company

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
45,043 45,043
32% 32%
100%
- Direct Costs 8,418 8,418
19% 19%
19%
36,624 36,624
35% 35%
81%
- Selling and Administrative Expenses 6,827 6,827
16% 16%
15%
- Research and Development Expense 10,991 10,991
18% 18%
24%
18,807 18,807
59% 59%
42%
- Depreciation and Amortization 1,767 1,767
16% 16%
4%
EBIT (Operating Income) EBIT 17,040 17,040
65% 65%
38%
Net Profit 10,590 10,590
102% 102%
24%

In millions USD.

Don't miss a Thing! We will send you all news about Eli Lilly and Company directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eli Lilly and Company Stock News

Neutral
Seeking Alpha
about one hour ago
Eli Lilly's recent Phase III results for its oral weight loss pill have demonstrated remarkable results. LLY has emerged as the frontrunner to tap into the next stage of growth through Orforglipron, potentially surpassing Novo Nordisk. Lilly's domestic capacity could provide it an edge against Denmark-based NVO, although supply chain risks imputed to tariffs cannot be downplayed.
Neutral
The Motley Fool
about 4 hours ago
Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the first of several phase 3 drug trials.
Negative
The Motley Fool
about 18 hours ago
One of the more interesting aspects about President Donald Trump's recent tariffs is that each major industry has shown at least some degree of weakness, regardless of whether the policies have directly affected them yet.
More Eli Lilly and Company News

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Head office United States
CEO David Ricks
Employees 47,000
Founded 1876
Website www.lilly.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today